Vera Therapeutics, Inc. (VERA)
| Market Cap | 2.66B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -299.62M |
| Shares Out | 71.71M |
| EPS (ttm) | -4.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,634,676 |
| Open | 37.65 |
| Previous Close | 37.28 |
| Day's Range | 36.71 - 38.97 |
| 52-Week Range | 18.76 - 56.05 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 81.30 (+119.08%) |
| Earnings Date | May 6, 2026 |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price target is $81.3, which is an increase of 119.08% from the latest price.
News
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation C...
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients wi...
Vera Therapeutics Appoints Christopher Hite to Board of Directors
BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients wi...
Vera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Atacicept is on track for FDA approval in July, with no major review or supply issues anticipated. The commercial strategy targets a broad U.S. market, leveraging a patient-friendly auto-injector and robust payer engagement. Pipeline efforts include expanded indications and longer-acting formulations.
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine U.S....
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Atacicept is on track for a July 2026 commercial launch in IgAN, supported by strong phase III efficacy and safety data, robust financials, and a dedicated commercial team. Ongoing trials and new formulations aim to expand its reach, with updated guidelines and additional data expected this year.
FDA Fast-Tracks Vera's At-Home Kidney Drug
Vera Therapeutics Inc. (NASDAQ: VERA) stock rose Wednesday after the U.S. Food and Drug Administration (FDA) accepted the company's atacicept Biologics License Application (BLA) for Priority Review.
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
Wells Fargo sees short squeeze ahead: here are three stocks to play it
Wells Fargo analysts believe a combination of tax refund spending, stronger earnings in lagging sectors, and fresh liquidity from the Federal Reserve could spark a “reflation” in equities. In a note l...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...
Vera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025
Atakicept's positive Phase III results in IgAN nephropathy support a BLA filing, with a potential July PDUFA date. The drug offers a novel, safe, and effective B cell-targeted therapy, with an autoinjector launch planned and expansion into other autoimmune kidney diseases underway.
Vera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Phase 3 data for atacicept in IgA nephropathy showed strong efficacy and safety, supporting a planned U.S. launch in 2026. The pipeline is expanding into broader kidney and autoimmune indications, with monthly and long-interval dosing in development.
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
Recent clinical data show atacicept achieved significant reductions in proteinuria and hematuria, with GFR stability over two years and a favorable safety profile. Regulatory filings are underway, and broader studies in autoimmune kidney diseases are ongoing, with more data expected into 2026.
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% r...
Vera Therapeutics Transcript: KOL Event
Atacicept's Phase III interim results show strong efficacy and safety in IgA nephropathy, with significant reductions in proteinuria and favorable biomarker outcomes across all patient subgroups. The product is highly anticipated by nephrologists, and the company is financially prepared for a 2026 launch and further pipeline expansion.
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy (IgAN) were presented as a...
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology ...
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
BRISBANE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Transcript: Cantor Global Healthcare Conference 2025
Atacicept has demonstrated robust, consistent efficacy in IgA nephropathy, with a BLA filing planned for Q4 and anticipated market entry by mid-next year. Commercial preparations are advanced, the auto-injector is well received, and the pipeline is expanding into broader kidney and autoimmune indications.